JOINT ACTION 3

Home  /  JOINT ACTION 3 (Page 2)

EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the diagnostic accuracy of molecular methods that detect the presence of SARS-CoV-2 virus in people with suspected COVID-19” is now available. This is the second rapid review assessing health technologies

The Other Technologies Collaborative Assessment OTCA23 final assessment report "Biodegradable rectum spacers to reduce toxicity for prostate cancer'', together with related documentation, is now available for access. The assessed technology is biodegradable rectum spacers added to conventional radiotherapy to (temporarily) position

The final project plan of the assessment on “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)” is now available. Comments from external experts and answers of the Authoring Team are also accessible. This

This is the pharmaceutical Joint Assessment PTJA12 - on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly

This is the pharmaceutical Joint Assessment PTJA10 – Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older. In October, 2020, the European Commission granted conditional marketing authorisation for Adakveo® (crizanlizumab) for the